2Seventy Bio Inc

2Seventy Bio — 2023 ASH Annual Meeting

26 slides from 2Seventy Bio's conference presentation, Dec 12, 2023

  1. Slide 1: 2023 ASH Annual Meeting Clinical Data

    2023 ASH Annual Meeting Clinical Data December 12, 2023

  2. Slide 2: Cautionary note regarding forward-looking statements

    2 Cautionary note regarding forward-looking statements These slides and the accompanying oral presentation may contain “forward-looking statements”. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, m

  3. Slide 3: Agenda for Today

    3 Opening Remarks ABECMA Data ABECMA Commercial Updates and Closing Remarks Q&A Nick Leschly, chief kairos officer Anna Truppel-Hartmann, M.D., SVP, clinical development Steve Bernstein, M.D., chief medical officer Chip Baird, chief operating officer All TOPIC SPEAKER Agenda for Today

  4. Slide 4: The sole mission of 2seventy is to unleash the curative potential of the T cell

    The sole mission of 2seventy is to “unleash the curative potential of the T cell” Our experience in drug development and deep execution capabilities in cell therapy allow us to design & deliver multi-layered, multi-modality T cell-based solutions that have the potential to address and overcome the i

  5. Slide 5: Key questions informed by ASH 2023 data

    Key questions informed by ASH 2023 data 5 What is the potential profile of Abecma in front line? What did we learn from KarMMa-3 in terms of OS? What does this mean for Abecma in the 3L+ commercial setting? What are you doing to shift the dynamics in the market? • KarMMa-2c data demonstrate potentia

  6. Slide 6: KarMMa-2c

    KarMMa-2c eseventybio/

  7. Slide 7: KarMMa-2c: Deepened responses in patients with inadequate response to frontline ASCT

    KarMMa-2c: Deepened responses in patients with inadequate response to frontline ASCT (<VGPR) 7 The bar starts at month 2, day 1 (equivalent to 1 month post ide-cel infusion) and continues to later of last response assessment date or data cutoff date (May 3, 2023). Response was defined as ≥ PR based

  8. Slide 8: KarMMa-2c: deep and durable responses support KarMMa-9 design

    KarMMa-2c: deep and durables responses in suboptimal ASCT responders support KarMMa-9 design KarMMa-2c data support conviction in transformative potential of ABECMA in front-line setting 8 • With a median follow-up of 39.4 months, the ORR in patients treated with Abecma (n=31) was 87.1% (95% CI: 70.

  9. Slide 9: KarMMa-3

    KarMMa-3 9Rodríguez-Otero P, et al. ASH 2023 Abstract 1028

  10. Slide 10: KarMMa-3 study design (NCT03651128)

    KarMMa-3 study design (NCT03651128) 10 ➤ KarMMa-3 updated analysis R 2:1 Key inclusion criteria • 2-4 previous regimens (including an IMiD agent, PI, and daratumumab) • Refractory to the last regimen Stratification factors • Age (< 65 vs ≥ 65 years) • Number of previous regimens (2 vs 3 or 4) • High

  11. Slide 11: Heavily Pretreated, Triple Class Exposed Patient Population

    Heavily Pretreated, Triple Class Exposed Patient Population 11 ➤ KarMMa-3 updated analysis Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 Characteristic Ide-cel (n = 254) Standard regimens (n = 132) Median (range) age, years 63 (30–81) 63 (42–83) Median (range) time from diagnosis to screening, ye

  12. Slide 12: Significant benefit with ide-cel at final PFS analysis (ITT population)

    Significant benefit with ide-cel at final PFS analysis (ITT population) 12Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis PFS was analyzed in the ITT population of all randomized patients in both arms and included early PFS events occurring between randomization and ide-

  13. Slide 13: Statistically significant, deep and durable responses with ide-cel

    10 26 18 11 41 5 0 20 40 60 80 100 Ide-cel Standard regimens Statistically significant, deep and durable responses with ide-cel Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis Per IMWG criteria. Individual responses may not sum to ORR due to rounding. aOR is for ORR, cal

  14. Slide 14: OS analysis confounded by substantial crossover

    Information fraction for OS was 74% (n = 164/222 required events). aBased on Kaplan–Meier approach; bStratified HR is based on the univariate Cox proportional hazards model. CI is 2-sided and calculated by bootstrap method; cTwo-stage Weibull model without recensoring (prespecified analysis). NR, no

  15. Slide 15: Patients who never received ide-cel drive imbalance in early OS events

    Patients who never received ide-cel drive imbalance in early OS events 15Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 aAll 4 cases of “death from other cause” in the ide-cel arm were reported verbatim as ”unknown”, which was coded under the system organ class of “general disorder and administrat

  16. Slide 16: Suboptimal bridging therapy

    Suboptimal bridging therapy 16 Cumulative dose during bridging therapy for the ide-cel arm and cycles 1 and 2 for the standard regimens arm was defined as the sum of all doses taken in mg. Dose intensity was defined as the cumulative dose divided by total days. aFor patients in the ide-cel arm, brid

  17. Slide 17: Trend of OS benefit with ide-cel among treated patients

    Trend of OS benefit with ide-cel among treated patients 17Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis aBased on Kaplan–Meier approach; bStratified HR based on the univariate Cox proportional hazards model. CI is two-sided. O S (% ) HR 0.83 (95% CI, 0.58–1.18) Median

  18. Slide 18: KarMMa-3 Data Supports Potential of Abecma in Earlier Lines

    KarMMa-3 Data Supports Potential of Abecma in Earlier Lines 18 • KarMMa-3 demonstrates a significantly longer and clinically meaningful improvement of PFS with ide-cel versus standard regimens in patients with early line relapse and triple-class exposed (TCExp) RRMM across all subgroups1 – 51% reduc

  19. Slide 19: Abecma Data at ASH Reinforce Potential in Earlier Lines and Differentiated Safety Profile

    Abecma Data at ASH Reinforce Potential in Earlier Lines and Differentiated Safety Profile ➤ Encouraging phase II data in patients with suboptimal response to ASCT ➤ ORR: 87.1%; CRR: 77.4%, at 36mts PFS was 76.8% ➤ None of 8 patients with lenalidomide maintenance after ide-cel progressed ➤ These data

  20. Slide 20: Commercial Update and Closing

    Commercial Update and Closing 20Rodríguez-Otero P, et al. ASH 2023 Abstract 1028

  21. Slide 21: ABECMA return to growth driven by label expansion, increased capacity and market growth

    2023 2022 2024-2030+ ABECMA® return to growth driven by label expansion, increased capacity and double-digit market growth 21*US ABECMA profit and loss shared 50/50 between 2seventy and BMS as part of the collaboration agreement; unaudited, based on information currently available and subject to cha

  22. Slide 22: Thank You

    THANK YOU 22Rodríguez-Otero P, et al. ASH 2023 Abstract 1028

  23. Slide 23: Appendix

    APPENDIX 23Rodríguez-Otero P, et al. ASH 2023 Abstract 1028

  24. Slide 24: Figure 1. KarMMa-2 cohort study design

    Figure 1. KarMMa-2 cohort 2 study design 24 Cohort 2c: ORR, VGPR rate, TTR, DOR, PFS, TTP, OS, safety, PK, immunogenicity (anti-CAR antibody response), HRQoL Post-treatment follow-up period Minimum 24 months or until PD post–ide-cel infusion, whichever is longerb Post-treatment follow-up discontinua

  25. Slide 25: Patient disposition

    Patient disposition 25Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis aFollowing IRC-confirmed PD. Percentages used the standard regimens ITT population (n = 132) as the denominator; bAll randomized patients; cPatients who received the study treatment to which they were

  26. Slide 26: Safety summary

    Safety summary 26 Patients, n (%) Ide-cel (n = 225) Standard regimens (n = 126) Any grade AE 225 (100) 124 (98) Grade 3/4 AE 210 (93) 97 (77) Grade 5 AE 28 (12) 9 (7) SAE 105 (47) 52 (41) Patients, n (%) Ide-cel (n = 254) Standard regimens (n = 132) Overall number of deaths 106 (42) 58 (44) Cause of

2seventy bio — 2023 ASH Annual Meeting on 6ix